Pharma BD Deal Intelligence
A $520M biobucks deal for a single anti-IL-8 antibody that never left early-stage trials in nine years. BMS gained HuMax-IL8 (BMS-986253) from Swedish biotech Cormorant, but Phase 1 showed zero objective tumor responses and the pivotal combination with nivolumab/ipilimumab in melanoma failed to beat checkpoint inhibitors alone.
A $520M-headline biobucks deal for a single IL-8 antibody that never left Phase 1/2 and never hit an endpoint in nine years
Full analysis, sources & comparables →Original 2012 Genmab-to-Cormorant exclusive license agreement that brought HuMax-IL8 into Cormorant's pipeline, creating the asset BMS later acquired in the…
Pharma Manufacturing emphasized the heavily back-loaded structure ($95M upfront vs $425M milestones), characteristic of early-clinical IO assets where buyers…
C&EN traced the asset's pedigree: Genmab licensed HuMax-IL8 to Cormorant in 2012; Genmab originally obtained it from Medarex (which BMS acquired for $2.4B in…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
BMS acquired Stockholm-based Cormorant Pharmaceuticals for up to $520M (undisclosed upfront cash plus contingent milestones tied to pipeline progression). Gained full rights to HuMax-IL8, an early-to-mid-stage anti-IL-8 antibody in development as a single agent and in combination with other immuno-oncology drugs. Genmab originally licensed HuMax-IL8 to Cormorant.
A $520M-headline biobucks deal for a single IL-8 antibody that never left Phase 1/2 and never hit an endpoint in nine years
Assessment window: 5yr post-close.
Interleukin-8 (CXCL8) is a pro-inflammatory chemokine secreted by many solid tumors that recruits myeloid-derived suppressor cells (MDSCs) and neutrophils to the tumor microenvironment, suppressing T-cell function and supporting metastasis. Anti-IL-8 therapy was hypothesized to remove an immunosuppressive brake and combine synergistically with PD-1/PD-L1 checkpoint inhibitors across solid tumors.
In 2016, BMS led the IO category with Opdivo (nivolumab) and Yervoy (ipilimumab), but checkpoint inhibitor monotherapy showed durable benefit in only ~20-30% of patients, driving an arms race to find combination partners that expand response. The IL-8/CXCR1/CXCR2 axis competed with other myeloid-targeted approaches: AstraZeneca's danvatirsen (STAT3 ASO), Syndax/Incyte's axatilimab (anti-CSF1R), Boehringer's BI 765063 (anti-SIRPα), and various IDO/TDO inhibitors. HuMax-IL8 (BMS-986253) was differentiated as the only clinical-stage anti-IL-8 antibody, with biomarker rationale supported by serum IL-8 as a prognostic factor for IO response. BMS's $520M deal — $95M upfront plus $425M in regulatory milestones — secured full rights to the asset (originally Genmab/Medarex IP) for combination with Opdivo. Asset progressed into Phase 1/2 combination trials but has not advanced to registration as of 2025, mirroring the broader struggle of IO+X combinations to deliver pivotal wins.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Cormorant Pharmaceuticals AB (this deal) | 2016 | $520M | 25 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2016 deals · Bristol-Myers Squibb Company deals · Oncology deals